Clinical trials: Breast
Breast Cancer
Breast Cancer Risk Reduction: A Patient Doctor Intervention
The proposed research combines the scientific advances in breast cancer research with health information technology (IT) to design a personalized intervention that assesses breast cancer risk for women, disseminates important…
- Trial name
- BreastCARE (NCT01830933)
- Testing
- BreastCARE
- Where
- 2 sites in United States
- Volunteers
- 1,235 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Ductal Carcinoma
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
The purpose of this study is to determine if an oncolytic virus called Talimogene laherparepvec (a modified herpes simplex 1 virus that can specifically destroy cancer cells while leaving normal cells alone) injected directly…
- Conditions
- Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
- Trial name
- NCT02779855
- Testing
- Talimogene laherparepvec, Paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
This study is looking at a new drug called AZD4547 which is being tested for the treatment of oestrogen receptor positive breast cancer.
- Trial name
- RADICAL (NCT01791985)
- Testing
- AZD4547 / anastrozole or letrozole
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Imperial College London
Breast Cancer
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D…
- Trial name
- VITAL (NCT00867217)
- Testing
- High Dose Vitamin D, Standard Dose Vitamin D3, Letrozole 2.5mg
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- Qamar Khan
Metastatic HER2-Positive Breast Cancer
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side…
- Trial name
- NCT02252887
- Testing
- Gemcitabine, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Docetaxel in Node Positive Adjuvant Breast Cancer
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable…
- Trial name
- TAX316 (NCT00688740)
- Testing
- Docetaxel, 5-fluorouracil, Doxorubicin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 1,491 people
- Sponsor
- Sanofi
Breast Cancer
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00895414
- Testing
- doxorubicin hydrochloride, enalapril maleate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Triple Negative Breast Cancer
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib [AZD6738]) and…
- Trial name
- NCT03330847
- Testing
- Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Where
- 141 sites in United States, Belgium and 13 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Breast Cancer
Brain Mets - Capecitabine Plus Sunitinib and WBRT
The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast…
- Trial name
- NCT00570908
- Testing
- sunitinib, capecitabine, WBRT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor Breast Care Center
Hereditary Cancer Syndrome
Cancer Health Assessments Reaching Many
The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations.
- Trial name
- CHARM (NCT03426878)
- Testing
- Modified genetic counseling, Traditional genetic counseling
- Where
- 2 sites in United States
- Volunteers
- 967 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Breast Neoplasm
Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.
- Trial name
- NCT00779285
- Testing
- Pegylated Liposomal Doxorubicin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Advanced MRI Sequences for Radiation Therapy Treatment Planning
The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment planning or treatment follow-up MRI.
- Trial name
- NCT02340715
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery kill any remaining tumor cells and may be an effective treatment for breast cancer.
- Trial name
- NCT01082211
- Testing
- 3D-Conformal External Beam
- Where
- 58 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Radiation Therapy Oncology Group
Delay in Time to Lactogenesis Stage II
Postpartum Family Planning
Investigators will conduct a randomized controlled trial (RCT) to evaluate the effects of immediate postpartum initiation of DMPA on breastfeeding and long-term contraceptive use.
- Trial name
- NCT03844633
- Testing
- Depo-Provera Injectable Product
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Breast Cancer
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant…
- Trial name
- NCT00503906
- Testing
- Avastin, Gemcitabine, Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Breast Cancer Metastatic
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
Primary Objective: To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic…
- Trial name
- AMEERA-3 (NCT04059484)
- Testing
- Amcenestrant, Fulvestrant, Anastrozole
- Where
- 109 sites in United States, Argentina and 21 more
- Volunteers
- 367 people
- Sponsor
- Sanofi
Ovarian Cancer, Breast Cancer
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
- Trial name
- NCT05258747
- Testing
- Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Sandoz
Metastatic Breast Cancer
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD)…
- Trial name
- FRIDA (NCT02370238)
- Testing
- paclitaxel, Reparixin
- Where
- 77 sites in United States, Belgium and 5 more
- Volunteers
- 194 people
- Sponsor
- Dompé Farmaceutici S.p.A
Breast Cancer
Personalized Treatment Selection for Metastatic Breast Cancer
The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).
- Trial name
- NCT00780676
- Testing
- Dasatinib, AZD6244
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Aromatase Inhibitor Host Factors Study
The purpose of this study is to examine how key patient factors, including body size affect how well letrozole suppresses circulating estrogen levels.
- Trial name
- NCT01669343
- Testing
- Letrozole
- Where
- 3 sites in Canada
- Volunteers
- 121 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.